Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004108 · ClinicalTrials.gov registry record · Phase 2
DX-8951f in Treating Patients With Liver Cancer
A Phase 2 study of Liver Cancer, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 2
- Development phase
- 4
- Study locations
NCT00004108 is a Phase 2 study of Liver Cancer that has completed, run by Daiichi Sankyo. The trial reports 4 study locations across 3 states.
The verdict
NCT00004108, a Phase 2 study of Liver Cancer, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating patients who have liver cancer.
Conditions Studied
Interventions
- DRUG exatecan mesylate
Study Locations (4)
Texas
- University of Texas - MD Anderson Cancer Center - Houston
- Cancer Therapy & Research Center - San Antonio
Colorado
- University of Colorado Cancer Center - Denver
New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-09 |
| Est. Completion | 2005-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004108
The ClinicalTrials.gov registry entry for NCT00004108 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Liver Cancer appearing as the primary indexed condition, and to 1 intervention - of which exatecan mesylate is the first listed.
NCT00004108 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Texas, Colorado, New York.
Frequently Asked Questions
What is clinical trial NCT00004108 about?
NCT00004108 is a clinical study titled "DX-8951f in Treating Patients With Liver Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating patients who have liver cancer.
What is the current status of trial NCT00004108?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-09. Estimated completion is 2005-04.
What conditions does trial NCT00004108 study?
This clinical trial studies the following conditions: Liver Cancer.
What interventions are being tested in trial NCT00004108?
The interventions under investigation include: exatecan mesylate (DRUG).
Who is sponsoring clinical trial NCT00004108?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00004108 being conducted?
This trial has 4 study locations across Colorado, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
RECRUITING · Phase 2
-
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
RECRUITING · Phase 2
-
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RECRUITING · Phase 2
-
Y-90 Treatment Response Using Transarterial Radioembolization
RECRUITING · Phase 2
-
Domvanalimab and Zimberelimab in Advanced Liver Cancers
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.